Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 2 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 8 hours agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 15 hours agoThe studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is already...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 22 hours agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 8 hours agoEverything you need to know about the art and science of drug naming in five minutes or less,...
General Partner Inc. Buys 1,792 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 14 hours agoGeneral Partner Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 716.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission ...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Up 11.1% in May
ETF DAILY NEWS· 1 day agoArcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling ...
Optimist Retirement Group LLC Purchases New Shares in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 6 days agoOptimist Retirement Group LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange ...
Cantor Fitzgerald L. P. Invests $33,000 in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
ETF DAILY NEWS· 7 days agoCantor Fitzgerald L. P. bought a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought ...
Biogen Inc. (NASDAQ:BIIB) Receives $286.50 Consensus Target Price from Analysts
ETF DAILY NEWS· 5 days agoShares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-six brokerages that are covering the firm, MarketBeat Ratings ...